<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03839524</url>
  </required_header>
  <id_info>
    <org_study_id>TG4050.01</org_study_id>
    <nct_id>NCT03839524</nct_id>
  </id_info>
  <brief_title>A Trial Evaluating TG4050 in Ovarian Carcinoma.</brief_title>
  <official_title>A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Transgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Transgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, single arm phase I study evaluating the safety and
      tolerability as well as some activity parameters of TG4050 in patients with ovarian,
      fallopian or peritoneal serous carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability (Adverse Event reported per CTCAE v5)</measure>
    <time_frame>At each study visit up to final safety follow up visit: every week for the first 6 weeks and then every 3 weeks</time_frame>
    <description>Incidence of Adverse Event reported per CTCAE v5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best overall response rate as assessed by the Gynecological Cancer Intergroup (GCIC) Carbohydrate Antigen 125 (CA-125) criteria</measure>
    <time_frame>Every 3 weeks</time_frame>
    <description>Percentage of patients with a minimum 50% reduction in CA-125 serum levels lasting for 28 days relative to pre-treatment CA-125 serum level per the GCIC criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Tumor Response Rate</measure>
    <time_frame>Within 21 days of treatment initiation and then every 9 weeks</time_frame>
    <description>Percentage of patients whose best overall response is either a Complete Response or a Partial Response according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) criteria over the the total number of patients evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with immune response</measure>
    <time_frame>Days 64, 85 and 211</time_frame>
    <description>Percentage of patients who achieve an immune response established by the detection of antigen-specific T cell.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">13</enrollment>
  <condition>Ovarian Carcinoma</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>TG4050 arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive injections of TG4050 Investigational Medicinal Product.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TG4050</intervention_name>
    <description>Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.</description>
    <arm_group_label>TG4050 arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent.

          2. Female patients ≥ 18 years

          3. Histologically confirmed high grade, advanced stage serous ovarian, fallopian tube or
             primary peritoneal carcinoma.

          4. Patients who have undergone primary debulking surgery and have completed standard
             first-line platinum-based chemotherapy for whom tumor tissue has been banked from
             previous abdominal surgery.

          5. Patients must have achieved a complete response to therapy

          6. Adequate hematological, hepatic and renal functions

        Exclusion Criteria:

          1. Patient having received:

               -  Neoadjuvant chemotherapy prior to debulking surgery

               -  Any cancer immunotherapy including cancer vaccines, any antibody/drug targeting T
                  cell co-regulatory proteins such as anti-Programmed cell death 1 (anti-PD1),
                  anti-Programmed death-ligand 1 (anti-PDL1) or anti-cytotoxic
                  T-lymphocyte-associated protein 4 (anti-CTL4)

          2. Patients with other active malignancy ≤ 3 years prior to registration except
             non-melanoma skin cancer, and stage 0 in situ carcinoma.

          3. Patient post-organ transplantation, including allogeneic stem cell or bone marrow
             transplantation

          4. Known history of positive testing for Human Immunodeficiency Virus (HIV) or known AIDS
             (Acquired Immune Deficiency Syndrome)

          5. Any known allergy or reaction to eggs or attributed to compounds of similar chemical
             or biological composition to therapeutic vaccines/immunotherapeutic products

          6. Acute or chronic infection with hepatitis C Virus (HCV) or Hepatitis B Virus (HBV)

          7. Major surgery within 4 weeks of treatment start

          8. Treatment with another investigation agent within 30 days prior to TG4050 treatment
             initiation.

          9. Patients under chronic treatment with systemic corticosteroids or other
             immunosuppressive drugs . Steroids with no or minimal systemic effect (topical,
             inhalation) are allowed.

         10. Use of non-oncology vaccine therapy for prevention of infectious diseases during the
             four-week period prior to TG4050 treatment initiation planned date.

         11. Uncontrolled intercurrent illness
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Transgene EU, Clinical Operations Department</last_name>
    <phone>+ 33.3.88.27.91.00</phone>
    <email>clinicaltrials@transgene.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IUCT Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 6, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

